Fyber N.V.

  • WKN: A2P1Q5
  • ISIN: NL0014433377
  • Land: Deutschland

Nachricht vom 04.08.2021 | 16:52

Fyber N.V.: Update Delisting

DGAP-News: Fyber N.V. / Key word(s): Delisting
04.08.2021 / 16:52
The issuer is solely responsible for the content of this announcement.

 

FYBER N.V.
Update Delisting of Fyber

Berlin, 4 August 2021 - Fyber N.V. ("Fyber" FSE:FBEN) announces, further to its announcement dated 8 July 2021, that the delisting of the Fyber shares from the Frankfurt Stock Exchange will be effective at close of business on 6 August 2021 which will then be the last trading day of the Fyber shares.

 

###

About Fyber
Fyber is a leading advertising technology company, developing a next generation platform for the programmatic trading of ads, in a data-driven environment. Our mission is to fuel the creation of quality content by empowering app developers to unlock the true value of their advertising properties through advanced technologies, innovative ad formats and data-driven decision-making. Fyber's technology platform provides an open-access platform for both digital advertisers and publishers with a global reach. Fyber has offices in Berlin, Tel Aviv, New York, San Francisco, London, Beijing and Seoul. For additional information visit www.fyber.com.

Investor Contact
Sabrina Kassmannhuber
ir@fyber.com
+49 30 609 855 555



04.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021